Australia’s leading digital medication management company, is pleased to announce it has formalised its agreement with EBOS subsidiary Zest, following EBOS Group’s investment in MedAdvisor back in October last year.
Under the agreement, MedAdvisor will provide a digital communication channel for Zest’s healthcare programs, enabling better connections with manufacturers and the community.
This partnership may extend further as the Company’s hospital market expansion strategy rolls out, through collaboration on tailored and customised hospital discharge programs. outcomes.
Shares in MedAdvisor (ASX: MDR) are trading flat at 4.2c.